PFIZER INC ($NYSE:PFE) reported their earnings for the second quarter of fiscal year 2023 on June 30th 2023, with total revenue being the same as the same quarter of the previous year, at USD 12.7 billion. Net income was also equal to that of the same quarter of the prior year, at USD 2.3 billion.
The company’s stock opened at $35.6 and closed at $35.8, up by 0.6% from its previous closing price of $35.6. In the second quarter, PFIZER INC reported total revenues of USD 10 billion, driven by higher sales of its key products, including Lyrica, Eliquis, Xeljanz and Ibrance. In the earnings call, PFIZER INC CEO Albert Bourla stated that they are continuing to invest in research and development activities to build a strong portfolio of innovative products and technologies. He further added that the company is well-positioned to capitalize on the growing demand for innovative medicines and therapies around the world.
Overall, PFIZER INC has reported a steady performance in the second quarter of FY2023 with solid growth in revenues and earnings. With a strong pipeline of products and technologies in the works, the company is well-positioned to benefit from the growing global demand for innovative medicines and therapies. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Pfizer Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pfizer Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pfizer Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Pfizer Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale analyzed PFIZER INC‘s financials and concluded that the company is in a healthy state, scoring 8/10 on our Star Chart. This score is based on the company’s cashflows and debt, indicating that it is capable of sustaining operations in times of crisis. Furthermore, PFIZER INC is strong in dividend and profitability, and of medium strength in asset and growth. We have classified PFIZER INC as a ‘rhino’ company, as it has achieved moderate levels of revenue or earnings growth. We believe that this company would interest value-oriented investors who are looking for long-term investments with steady returns. More…
Risk Rating Analysis
Star Chart Analysis
In the pharmaceutical industry, competition is fierce between companies striving to bring innovative new drugs to market. Among the leaders in this industry are Pfizer Inc and its competitors Astellas Pharma Inc, Roche Holding AG, and AstraZeneca PLC. While each company has its own strengths and weaknesses, they all share a commitment to research and development in an effort to stay ahead of the competition.
– Astellas Pharma Inc ($TSE:4503)
Astellas Pharma Inc is a Japanese pharmaceutical company with a market cap of 3.61T as of 2022. The company’s ROE is 6.6%. Astellas Pharma is engaged in the research, development, manufacture, and marketing of pharmaceutical products. The company’s products include ethical drugs, over-the-counter drugs, and generic drugs. Astellas Pharma also has a clinical research division that conducts clinical trials of new drugs.
Roche Holding AG is a multinational pharmaceutical company headquartered in Basel, Switzerland. The company was founded in 1896 by Fritz Hoffmann-La Roche. Roche is the world’s largest biotech company, with products in the areas of pharmaceuticals, diagnostics, and consumer health. The company’s mission is to “improve lives by enabling people to do more, feel better, and live longer.”
Roche Holding AG has a market cap of 270.34B as of 2022, a Return on Equity of 47.83%. The company’s strong market position and financial performance are due to its innovative products and services, which address a broad range of medical needs. Roche is committed to research and development, and has a strong pipeline of new products in development. The company’s focus on customer needs and its ability to bring new products to market quickly have resulted in strong financial performance and shareholder value.
– AstraZeneca PLC ($LSE:AZN)
AstraZeneca PLC is a pharmaceutical company with a market cap of 152.81 billion as of 2022. The company has a return on equity of -0.94%. AstraZeneca PLC is engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and biologic products for the treatment of cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory diseases.
PFIZER INC had a strong performance in the second quarter of FY2023, reporting total revenue of USD 12.7 billion and net income of USD 2.3 billion with no change year over year. This is an encouraging sign for investors, suggesting that the company is well-positioned to continue delivering consistent returns. Further, given the positive outlook for the pharmaceutical industry, PFIZER INC looks to be a sound investment opportunity. With a strong balance sheet, low debt-to-equity ratio, and competitive market position, investors can expect to see attractive returns from their PFIZER INC investments in the long term.